Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalbavancin - Durata Therapeutics

Drug Profile

Dalbavancin - Durata Therapeutics

Alternative Names: A-A-1; BI-397; Dalbavancin hydrochloride; Dalvance; MDL-63,397; V-Glycopeptide; VER 001; VGE; Xydalba; Zevan; Zeven

Latest Information Update: 28 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vicuron Pharmaceuticals
  • Developer Cipher Pharmaceuticals; Durata Therapeutics; Pfizer
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase II Bacterial endocarditis; Osteomyelitis
  • No development reported Bacterial infections; Catheter infections; Diabetic foot ulcer; Gonorrhoea; Pneumonia

Most Recent Events

  • 28 May 2019 No recent reports of development identified for phase-I development in Bacterial-infections(In infants, In neonates) in USA (IV, Infusion)
  • 15 Nov 2018 Cipher Pharmaceuticals plans to launch dalbavancin hydrochloride in Canada in first half of 2019
  • 04 Sep 2018 Registered for Skin and soft tissue infections in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top